Inosine: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +))
No edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
{{drugbox
{{drugbox
| IUPAC_name = Inosine
| Verifiedfields = changed
| image =
| Watchedfields = changed
| CAS_number = 58-63-9
| verifiedrevid = 461935819
| ATC_prefix = D06
| IUPAC_name = 9-[(2''R'',3''R'',4''S'',5''R'')-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-3''H''-purin-6-one
| ATC_suffix = BB05
| image = Inosine Wiki Str.png
| ATC_supplemental = {{ATC|G01|AX02}}
<!--Clinical data-->
| PubChem = 6021
| Drugs.com = {{drugs.com|international|inosine}}
| DrugBank = EXPT02378
| pregnancy_category =  
| C=10|H=12|N=4|O=5
| legal_status = OTC
| molecular_weight = 268.229 g/mol
| routes_of_administration =
 
<!--Pharmacokinetic data-->
| bioavailability =  
| bioavailability =  
| protein_bound =  
| protein_bound =  
| metabolism = [[Liver|Hepatic]]
| metabolism = [[Liver|Hepatic]]
| elimination_half-life =  
| elimination_half-life =
| pregnancy_category =
| legal_status =
| routes_of_administration =
}}


{{SI}}
<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 58-63-9
| ATC_prefix = D06
| ATC_suffix = BB05
| ATC_supplemental = {{ATC|G01|AX02}} {{ATC|S01|XA10}}
| PubChem = 6021
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB04335
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 5799
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 5A614L51CT
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = C00294
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 17596
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1556


 
<!--Chemical data-->
==Overview==
| C=10 | H=12 | N=4 | O=5
| molecular_weight = 268.23 g/mol
| smiles = c1[nH]c2c(c(=O)n1)ncn2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O
| InChI = 1/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10-/m1/s1
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C10H12N4O5/c15-1-4-6(16)7(17)10(19-4)14-3-13-5-8(14)11-2-12-9(5)18/h2-4,6-7,10,15-17H,1H2,(H,11,12,18)/t4-,6-,7-,10-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UGQMRVRMYYASKQ-KQYNXXCUSA-N
}}
'''Inosine''' is a [[nucleoside]] that is formed when [[hypoxanthine]] is attached to a [[ribose]] ring (also known as a [[ribofuranose]]) via a β-N<sub>9</sub>-[[glycosidic bond]].
'''Inosine''' is a [[nucleoside]] that is formed when [[hypoxanthine]] is attached to a [[ribose]] ring (also known as a [[ribofuranose]]) via a β-N<sub>9</sub>-[[glycosidic bond]].


Inosine is commonly found in [[tRNA]]s and is essential for proper translation of the genetic code in [[wobble base pair]]s.  
Inosine is commonly found in [[tRNA]]s and is essential for proper translation of the genetic code in [[wobble base pair]]s.


Knowledge of inosine metabolism has led to advances in [[immunotherapy]] in recent decades. Inosine monophosphate is oxidised by the enzyme inosine monophosphate dehydrogenase yielding xanthosine monophosphate, a key precursor in [[purine]] metabolism.  [[Mycophenolate mofetil]] is an anti-metabolite, anti-proliferative drug, used in the treatment of a variety of [[autoimmune]] diseases including [[Wegener's granulomatosis]].  The uptake of purine by actively dividing [[B cell]]s can exceed 8 times that of normal body cells and therefore this set of white cells (which cannot operate purine salvage pathways) is selectively targeted by the purine deficiency resulting from IMD inhibition.
Knowledge of inosine metabolism has led to advances in [[immunotherapy]] in recent decades. Inosine monophosphate is oxidised by the enzyme [[inosine monophosphate dehydrogenase]], yielding [[xanthosine monophosphate]], a key precursor in [[purine]] metabolism.  [[Mycophenolate mofetil]] is an anti-metabolite, anti-proliferative drug that acts as an inhibitor of inosine monophosphate dehydrogenase. It is used in the treatment of a variety of [[autoimmune]] diseases including [[granulomatosis with polyangiitis]] because the uptake of purine by actively dividing [[B cell]]s can exceed 8 times that of normal body cells, and, therefore, this set of white cells (which cannot operate purine salvage pathways) is selectively targeted by the purine deficiency resulting from Inherited Metabolic Diseases (IMD) inhibition.


==Reactions==
==Reactions==
[[Adenine]] is converted to [[adenosine]] or [[Inosine monophosphate|IMP]], either of which in turn is converted into inosine (I), which pairs with [[adenine]] (A), [[cytosine]] (C) and [[uracil]] (U).  
[[Adenine]] is converted to [[adenosine]] or [[inosine monophosphate]] (IMP), either of which, in turn, is converted into inosine (I), which pairs with Adenine (A), [[cytosine]] (C), and [[uracil]] (U).


[[Purine nucleoside phosphorylase]] intraconverts inosine and [[hypoxanthine]].
[[Purine nucleoside phosphorylase]] intraconverts inosine and [[hypoxanthine]].


Inosine is also an intermediate in a chain of purine nucleotides reactions required for muscle movements.  
Inosine is also an intermediate in a chain of purine nucleotides reactions required for muscle movements.


==Clinical significance==
==Clinical significance==
It was tried in the seventies in eastern countries for improving athletic performance, based on the fact that is an intermediate compound used in the muscle movements. Nevertheless the clinical trials with this purpose showed no improvement.<ref>{{cite journal |author=McNaughton L, Dalton B, Tarr J |title=Inosine supplementation has no effect on aerobic or anaerobic cycling performance |journal=International journal of sport nutrition |volume=9 |issue=4 |pages=333-44 |year=1999 |pmid=10660865 |doi=}}</ref>
It was tried in the 1970s in Eastern countries for improving athletic performance. Nevertheless, the clinical trials for this purpose showed no improvement.<ref>{{cite journal |title=Inosine supplementation has no effect on aerobic or anaerobic cycling performance |journal=International journal of sport nutrition |volume=9 |issue=4 |pages=333–44 |year=1999 |pmid=10660865 |doi= |author1=McNaughton L |author2=Dalton B |author3=Tarr J |author-separator=,}}</ref>
It has been shown that inosine has neuroprotective properties. It has been proposed for spinal cord injury;<ref>{{cite journal |title=Secondary degeneration reduced by inosine after spinal cord injury in rats |journal=Spinal Cord |volume=44 |issue=7 |pages=421–6 |year=2006 |pmid=16317421 |doi=10.1038/sj.sc.3101878 |display-authors=3 |author1=Liu F |author2=You SW |author3=Yao LP |author-separator=, |last4=Liu |first4=HL |last5=Jiao |first5=XY |last6=Shi |first6=M |last7=Zhao |first7=QB |last8=Ju |first8=G}}</ref> because it improves axonal rewiring, and for administration after [[stroke]], because observation has shown that axonal re-wiring is encouraged.<ref>{{cite journal |title=Inosine induces axonal rewiring and improves behavioral outcome after stroke |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=99 |issue=13 |pages=9031–6 |year=2002 |pmid=12084941 |doi=10.1073/pnas.132076299 |url=http://www.pnas.org/cgi/content/full/99/13/9031 |author1=Chen P |author2=Goldberg DE |author3=Kolb B |author4=Lanser M |author5=Benowitz LI |author-separator=, |pmc=124418}}</ref>


Nowadays, it has been shown that inosine has neuroprotective properties. It has been proposed for administration after [[stroke]], because observation has shown that axonal re-wiring is encouraged.<ref>{{cite journal |author=Chen P, Goldberg DE, Kolb B, Lanser M, Benowitz LI |title=Inosine induces axonal rewiring and improves behavioral outcome after stroke |journal=Proc. Natl. Acad. Sci. U.S.A. |volume=99 |issue=13 |pages=9031-6 |year=2002 |pmid=12084941 |doi=10.1073/pnas.132076299 |url=http://www.pnas.org/cgi/content/full/99/13/9031}}</ref> It has been tried also for [[multiple sclerosis]] and is currently in phase II of the trials [http://www.clinicaltrials.gov/ct/show/NCT00067327].  
After ingestion, inosine produces uric acid that is suggested to be a natural antioxidant and a [[peroxynitrite]] scavenger with potential benefits to patients with [[multiple sclerosis]] (MS.)<ref name=":0">[http://www.webcitation.org/query?url=http://www.geocities.com/hotsprings/3468/uric_acid-peroxynitrite2-98.html&date=2009-10-26+00:12:14 Uric Acid: Natural Scavenger Of Peroxynitrite<!-- Bot generated title -->]</ref> Peroxynitrite has been correlated with axon degeneration [http://www.fedem.org/revista/n17/neuhausing.htm]. In 2003, a study was initiated at the University of Pennsylvania MS Center to determine whether raising the levels of uric acid by the administration of inosine would slow the progression of MS.<ref>{{cite web|title=Treatment of Multiple Sclerosis Using Over the Counter Inosine|url=http://www.clinicaltrials.gov/ct/show/NCT00067327}}</ref> The study was completed in 2006 but the results were not reported to NIH. A subsequent publication hinted at potential benefits but the sample size (16 patients) was too small for a definitive conclusion.<ref>{{cite journal | title=The Treatment of Multiple Sclerosis with Inosine |journal=J Altern Complem Med |volume=15 |issue=6 |pages=619–625 |year=2009 |doi=10.1089/acm.2008.0513 |url=http://online.liebertpub.com/doi/abs/10.1089/acm.2008.0513?2 |author1=Markowitz CE |author2=Spitsin S | author3=Zimmerman V |author4=Jacobs D |author5=Udupa JK |author6=Hooper DC| author7=Koprowski H | pmid=19425822 | pmc=3189001}}</ref> In addition, the side effect of the treatment was the development of kidney stones in 4 out of 16 patients. Thus, additional studies are necessary to prove the treatment's efficacy.


It produces uric acid after ingestion, which is a natural antioxidant and a peroxinitrite scavenger, which can explain the behaviour in multiple sclerosis [http://www.geocities.com/hotsprings/3468/uric_acid-peroxynitrite2-98.html](peroxynitrite has been correlated with the axons degeneration [http://www.fedem.org/revista/n17/neuhausing.htm]).
It is also in phase II trials for Parkinson's disease. Earlier trials had suggested those with the highest serum urate levels had lower progression of Parkinson's symptoms. The trial uses inosine to raise urate levels in those with levels lower than the population mean (6&nbsp;mg/dL).<ref>{{cite web|title=Safety of Urate Elevation in Parkinson's Disease|url=https://foxtrialfinder.michaeljfox.org/trial/468/}}</ref><ref>{{cite web|title=Safety of Urate Elevation in Parkinson's Disease|url=http://clinicaltrials.gov/ct2/show/NCT00833690|publisher=ClinicalTrials.gov}}</ref>


Currently Boston Life Sciences holds the patent for treatment of stroke [http://www.bostonlifesciences.com/news111.htm] and this company is currently investigating its properties for MS under the name axosine for Multiple Sclerosis.
[[Alseres Pharmaceuticals]] (named Boston Life Sciences when patent was granted) patented the treatment for stroke [http://www.bostonlifesciences.com/news111.htm] and is currently investigating the drug in the MS setting.<ref>[http://www.alseres.com/product-pipeline/product-candidates/inosine.asp Alseres pharma drug description]</ref>
 
In the [[Anatomical Therapeutic Chemical Classification System]], it is classified as an [[Antiviral drug|antiviral]].<ref name="urlATC/DDD Index">{{cite web |url=http://www.whocc.no/atc_ddd_index/?code=D06BB05 |title=ATC/DDD Index |format= |work= |accessdate=}}</ref>


==Biotechnology==
==Biotechnology==
When designing [[primer (molecular biology)|primer]]s for [[polymerase chain reaction]], inosine is useful in that it will indiscriminately pair with adenine, thymine, or cytosine.  This allows one to design a primer that spans a [[single nucleotide polymorphism]], without worry that the polymorphism will disrupt the primer's annealing efficiency.
When designing [[primer (molecular biology)|primer]]s for [[polymerase chain reaction]], inosine is useful in that it can pair with adenine, thymine, or cytosine.  This allows for design of primers that span a [[single-nucleotide polymorphism]], without the polymorphism disrupting the primer's annealing efficiency.
 
However, inosine pairs preferentially with cytidine (C) and its introduction to RNA, e.g. by the action of ADARs, thereby destabilizes double stranded RNA by changing AU base-pairs to
IU mismatches (Bass and Weintraub, Cell, 1988).
 
==Fitness==
Despite  lack of clinical evidence that it improves muscle development, inosine remains an ingredient in some fitness supplements.
 
==Feeding Stimulant==
Inosine has also been found to be an important feed stimulant by itself or in combination with certain [[amino acids]] in some species of farmed [[fish]]. For example, inosine and inosine-5-monophosphate have been reported as specific feeding stimulants for [[turbot]] fry, (''Scophthalmus maximus'') <ref>Mackie, A.M. (1987). Identification of the gustatory feeding stimulants. In: Chemoreception in Fishes. (ed. T.J. Hara). Elsevier Scientific Publishing Co., Amsterdam, pp. 275-291.</ref> and [[Japanese amberjack]], (''Seriola quinqueradiata'').<ref>Takeda, M. Takii, K. & Matsui, K. (1984). Identification of feeding stimulants for juvenile eel. Bull. Jap. Soc. Scient. Fish., 50: 645-651.</ref> The main problem of using inosine and/or inosine-5-monophosphate as feeding attractants is their high cost. However, their use may be economically justified within larval feeds for marine fish larvae during the early weaning period, since the total quantity of feed consumed is relatively low.
 
==See also==
*[[Inosine monophosphate dehydrogenase]]
*[[Inosine pranobex]]
*[[Nucleobase]]


==References==
==References==
<references/>
{{reflist|2}}


==External links==
==External links==
Line 57: Line 99:
{{Gynecological anti-infectives and antiseptics}}
{{Gynecological anti-infectives and antiseptics}}
{{Antivirals}}
{{Antivirals}}
[[Category:Nucleosides]]
[[Category:Nucleosides]]
[[Category:Purines]]
[[Category:Antivirals]]
[[Category:Antivirals]]
[[de:Inosin]]
[[es:Inosina]]
[[ja:イノシン]]
[[pl:Inozyna]]
[[zh:肌苷]]
{{WH}}
{{WikiDoc Sources}}

Latest revision as of 19:58, 6 April 2015

Inosine
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismHepatic
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC10H12N4O5
Molar mass268.23 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Inosine is a nucleoside that is formed when hypoxanthine is attached to a ribose ring (also known as a ribofuranose) via a β-N9-glycosidic bond.

Inosine is commonly found in tRNAs and is essential for proper translation of the genetic code in wobble base pairs.

Knowledge of inosine metabolism has led to advances in immunotherapy in recent decades. Inosine monophosphate is oxidised by the enzyme inosine monophosphate dehydrogenase, yielding xanthosine monophosphate, a key precursor in purine metabolism. Mycophenolate mofetil is an anti-metabolite, anti-proliferative drug that acts as an inhibitor of inosine monophosphate dehydrogenase. It is used in the treatment of a variety of autoimmune diseases including granulomatosis with polyangiitis because the uptake of purine by actively dividing B cells can exceed 8 times that of normal body cells, and, therefore, this set of white cells (which cannot operate purine salvage pathways) is selectively targeted by the purine deficiency resulting from Inherited Metabolic Diseases (IMD) inhibition.

Reactions

Adenine is converted to adenosine or inosine monophosphate (IMP), either of which, in turn, is converted into inosine (I), which pairs with Adenine (A), cytosine (C), and uracil (U).

Purine nucleoside phosphorylase intraconverts inosine and hypoxanthine.

Inosine is also an intermediate in a chain of purine nucleotides reactions required for muscle movements.

Clinical significance

It was tried in the 1970s in Eastern countries for improving athletic performance. Nevertheless, the clinical trials for this purpose showed no improvement.[1] It has been shown that inosine has neuroprotective properties. It has been proposed for spinal cord injury;[2] because it improves axonal rewiring, and for administration after stroke, because observation has shown that axonal re-wiring is encouraged.[3]

After ingestion, inosine produces uric acid that is suggested to be a natural antioxidant and a peroxynitrite scavenger with potential benefits to patients with multiple sclerosis (MS.)[4] Peroxynitrite has been correlated with axon degeneration [1]. In 2003, a study was initiated at the University of Pennsylvania MS Center to determine whether raising the levels of uric acid by the administration of inosine would slow the progression of MS.[5] The study was completed in 2006 but the results were not reported to NIH. A subsequent publication hinted at potential benefits but the sample size (16 patients) was too small for a definitive conclusion.[6] In addition, the side effect of the treatment was the development of kidney stones in 4 out of 16 patients. Thus, additional studies are necessary to prove the treatment's efficacy.

It is also in phase II trials for Parkinson's disease. Earlier trials had suggested those with the highest serum urate levels had lower progression of Parkinson's symptoms. The trial uses inosine to raise urate levels in those with levels lower than the population mean (6 mg/dL).[7][8]

Alseres Pharmaceuticals (named Boston Life Sciences when patent was granted) patented the treatment for stroke [2] and is currently investigating the drug in the MS setting.[9]

In the Anatomical Therapeutic Chemical Classification System, it is classified as an antiviral.[10]

Biotechnology

When designing primers for polymerase chain reaction, inosine is useful in that it can pair with adenine, thymine, or cytosine. This allows for design of primers that span a single-nucleotide polymorphism, without the polymorphism disrupting the primer's annealing efficiency.

However, inosine pairs preferentially with cytidine (C) and its introduction to RNA, e.g. by the action of ADARs, thereby destabilizes double stranded RNA by changing AU base-pairs to IU mismatches (Bass and Weintraub, Cell, 1988).

Fitness

Despite lack of clinical evidence that it improves muscle development, inosine remains an ingredient in some fitness supplements.

Feeding Stimulant

Inosine has also been found to be an important feed stimulant by itself or in combination with certain amino acids in some species of farmed fish. For example, inosine and inosine-5-monophosphate have been reported as specific feeding stimulants for turbot fry, (Scophthalmus maximus) [11] and Japanese amberjack, (Seriola quinqueradiata).[12] The main problem of using inosine and/or inosine-5-monophosphate as feeding attractants is their high cost. However, their use may be economically justified within larval feeds for marine fish larvae during the early weaning period, since the total quantity of feed consumed is relatively low.

See also

References

  1. ↑ McNaughton L; Dalton B; Tarr J (1999). "Inosine supplementation has no effect on aerobic or anaerobic cycling performance". International journal of sport nutrition. 9 (4): 333–44. PMID 10660865. Unknown parameter |author-separator= ignored (help)
  2. ↑ Liu F; You SW; Yao LP; et al. (2006). "Secondary degeneration reduced by inosine after spinal cord injury in rats". Spinal Cord. 44 (7): 421–6. doi:10.1038/sj.sc.3101878. PMID 16317421. Unknown parameter |author-separator= ignored (help)
  3. ↑ Chen P; Goldberg DE; Kolb B; Lanser M; Benowitz LI (2002). "Inosine induces axonal rewiring and improves behavioral outcome after stroke". Proc. Natl. Acad. Sci. U.S.A. 99 (13): 9031–6. doi:10.1073/pnas.132076299. PMC 124418. PMID 12084941. Unknown parameter |author-separator= ignored (help)
  4. ↑ Uric Acid: Natural Scavenger Of Peroxynitrite
  5. ↑ "Treatment of Multiple Sclerosis Using Over the Counter Inosine".
  6. ↑ Markowitz CE; Spitsin S; Zimmerman V; Jacobs D; Udupa JK; Hooper DC; Koprowski H (2009). "The Treatment of Multiple Sclerosis with Inosine". J Altern Complem Med. 15 (6): 619–625. doi:10.1089/acm.2008.0513. PMC 3189001. PMID 19425822.
  7. ↑ "Safety of Urate Elevation in Parkinson's Disease".
  8. ↑ "Safety of Urate Elevation in Parkinson's Disease". ClinicalTrials.gov.
  9. ↑ Alseres pharma drug description
  10. ↑ "ATC/DDD Index".
  11. ↑ Mackie, A.M. (1987). Identification of the gustatory feeding stimulants. In: Chemoreception in Fishes. (ed. T.J. Hara). Elsevier Scientific Publishing Co., Amsterdam, pp. 275-291.
  12. ↑ Takeda, M. Takii, K. & Matsui, K. (1984). Identification of feeding stimulants for juvenile eel. Bull. Jap. Soc. Scient. Fish., 50: 645-651.

External links

Retrieved from "https://www.wikidoc.org/index.php?title=Inosine&oldid=1083539"